BioSpace News Archive

Healogics®, the nation’s wound healing expert, is proud to announce the seventh annual Healogics National Diabetes Awareness Week from October 26 - 30.

Partnership Will Accelerate the Awareness and Adoption of Precision Oncology in Private Practices and Community Oncology Cancer Centers in the United States

Pharmaceutical Technology® and BioPharm International® are pleased to announce their first-ever 2020 Bio/Pharma Virtual Congress, taking place Wednesday, Nov. 11, from 8:30 a.m. to 4 p.m. EST.

Concerned healthcare providers in southeast Wisconsin issued a plea to the public : COVID-19 is real.

Kiniksa expects to initiate a dose-ranging Phase 2b clinical trial of vixarelimab in prurigo nodularis in the fourth quarter of 2020

BioVie Inc. (NASDAQ:BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, today announced that it will participate in the B. Riley Securities’ Liver Disease Therapeutics Day 2020 on Thursday, October 29, 2020 at 11:00 a.m. ET.

Simplify Medical, Inc., maker of the Simplify® Cervical Artificial Disc, announced today the completion of the Pre-Market Approval (PMA) submission for the 2-level Simplify Disc IDE Study to the U.S. Food and Drug Administration (FDA

Astrotech Corporation (NASDAQ: ASTC), today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 2,887,906 shares of Astrotech’s common stock, at a purchase price of $2.15 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about October 30, 2020, subject to the satisf

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present updated data from its Phase 1 study investigating the potential for CPI-006 to provide a novel immunotherapy approach for patients with COVID-19 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place November 9-14, 2020. The updated data from the COVID-19 program will be presented in a p

Shattuck Labs, Inc. (“Shattuck”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its presentation at the CD47|SIRPα Summit 2020 being held virtually November 4-5, 2020. Presentation Details Presentation Title: CD40 Enhances Type I Interferon